NCT00416650View on ClinicalTrials.gov

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

October 31, 2007

Study Completion Date

March 31, 2013

Conditions
Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

All patients will receive 150 mg orally daily

Trial Locations (4)

10021

Memorial Sloan-Kettering Cancer Center, New York

37232

Vanderbilt-Ingram Cancer Center, Nashville

60611

Northwestern Memorial Hospital, Chicago

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00416650 - Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter